Alaunos Therapeutics (TCRT) risk factors, FY2025 10-K

Alaunos Therapeutics's FY2025 10-K, filed Mar 31, 2026, lists 42 risk factors in 4 groups. Against the prior year's 61: 18 new, 37 dropped, 11 substantially reworded.

Open TCRT in Gloom →
Alaunos Therapeutics' chart, financials and news, free in your browser.Open TCRT in Gloom →
Risk factors listed
424 groups
New this year
18vs 61 last year
Dropped
37since the prior 10-K
Substantially reworded
11of those kept
Section length
15k wordsItem 1A

What the changes say

  • Alaunos Therapeutics shifted away from broad strategic alternatives to focus entirely on its early preclinical Obesity and Metabolic Disorders Program.

What changed since the prior 10-K

New

  • NewRISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS

    We are not actively pursuing broad strategic alternatives such as acquisitions, mergers, or sales of the Company. Our primary focus is advancing our internally developed small-molecule Obesity and Metabolic Disorders Program

    The company is not pursuing broad strategic alternatives and is instead focused on advancing its internally developed Obesity and Metabolic Disorders Program.

  • NewRISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS

    The process of advancing our Obesity and Metabolic Disorders Program is costly and resource-intensive. We have incurred, and will continue to incur, significant costs related to preclinical studies, formulation development, manufacturing, and regulatory activities

    Advancing the Obesity and Metabolic Disorders Program is costly and resource-intensive, and any future strategic transaction depends heavily on its perceived value and progress.

  • NewRISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS

    We have no committed sources of additional capital at this time. Accordingly, we could exhaust our current cash resources before we are able to meaningfully advance our Obesity and Metabolic Disorders Program, requiring the Company to raise additional capital on uncertain terms or at all

    The company has no committed sources of additional capital and could exhaust its cash resources before advancing the Obesity and Metabolic Disorders Program.

  • NewRISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS

    We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future

    Significant operating losses are expected to continue as the company advances its Obesity and Metabolic Disorders Program through the preclinical stage.

  • NewRISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS

    incur additional costs associated with current and future research, development and commercialization efforts and operations as a public company

    Future research, development, and commercialization efforts will incur additional costs, and raising capital may cause dilution or require relinquishing product rights.

  • NewRISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS

    If we are unable to successfully advance our obesity and metabolic disorders program or raise sufficient additional capital, our Board of Directors may ultimately decide to pursue a dissolution and liquidation

    If the company cannot advance its obesity program or raise sufficient capital, the Board may pursue dissolution and liquidation.

  • NewRISKS RELATED TO OUR BUSINESS

    Because we currently have only one full-time employee—our Chief Executive Officer—who performs or oversees multiple functions, and we rely on outside consultants (including for accounting and financial reporting functions)

    The company relies on a single full-time employee, the CEO, and outside consultants for financial reporting and other functions.

  • NewRISKS RELATED TO OUR BUSINESS

    We have no products approved for commercial sale and have not generated any revenue from product sales. We may never generate any revenue from product sales or become profitable and, if we achieve profitability, we may not be able to sustain it

    The company has no approved products, has never generated product revenue, and may never achieve or sustain profitability.

  • NewRISKS RELATED TO OUR BUSINESS

    enforce and defend intellectual property rights and claims

    The obesity program is in an early preclinical stage and faces significant risks through animal studies and IND-enabling studies.

  • NewRISKS RELATED TO OUR BUSINESS

    Our business is highly dependent on the success of our Obesity and Metabolic Disorders Program, which is in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and commercially launch a product

    The business depends heavily on the success of the Obesity and Metabolic Disorders Program, which has had no interactions with the FDA to date.

  • NewRISKS RELATED TO OUR BUSINESS

    potent for each desired indication. An NDA must also include significant information regarding the chemistry, manufacturing and controls for the product

    FDA approval of an NDA is expensive, uncertain, and subject to substantial agency discretion and potential Advisory Committee review.

  • NewRISKS RELATED TO OUR BUSINESS

    Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business

    Preclinical development is uncertain, and programs may experience delays or fail before reaching clinical trials.

  • NewRISKS RELATED TO OUR BUSINESS

    We face competition from entities that have developed or may develop programs for the medical needs we plan to address with our Obesity and Metabolic Disorders Program

  • NewRISKS RELATED TO OUR BUSINESS

    Our legacy TCR-T cell therapy programs and related intellectual property are no longer in active development and may not generate any meaningful value

  • NewRISKS RELATED TO OUR BUSINESS

    and development activities, pursuant to which we agreed to pay $285,000 in six installments through May 30, 2026. Residual obligations, including trial close-out and long-term follow-up, may result in limited ongoing payments or interactions

  • NewRISKS RELATED TO OUR BUSINESS

    Our ability to advance our Obesity and Metabolic Disorders Program depends on our ability to retain our remaining employee and consultants

  • NewRISKS RELATED TO OUR BUSINESS

    Any future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees

  • NewRISKS RELATED TO OUR INTELLECTUAL PROPERTY

    We license rights to products and technology that are important to our business, and we expect to enter into additional licenses in the future

Dropped

  • DroppedRISKS RELATED TO OUR STRATEGIC REPRIORITIZATION

    Even if we successfully consummate a transaction from our strategic assessment, we may fail to realize all of the anticipated benefits of the transaction, those benefits may take longer to realize than expected, or we may encounter integration difficulties

    Risks of failing to realize anticipated benefits or integration difficulties from strategic transactions.

  • DroppedRISKS RELATED TO OUR STRATEGIC REPRIORITIZATION

    If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks

    Operational and financial risks and management distraction from pursuing strategic transactions.

  • DroppedRISKS RELATED TO OUR STRATEGIC REPRIORITIZATION

    Any of the foregoing risks could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects

    Potential adverse effects and risk of dissolution if a strategic transaction is not consummated.

  • DroppedRISKS RELATED TO OUR STRATEGIC REPRIORITIZATION

    Our ability to consummate a strategic transaction depends on our ability to retain our remaining employee and consultants

    Dependence on retaining remaining employees and consultants following workforce reductions.

  • DroppedRISKS RELATED TO OUR STRATEGIC REPRIORITIZATION

    Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could significantly disrupt our business

    Corporate restructuring and headcount reduction risks following the discontinuation of clinical programs.

  • DroppedRISKS RELATED TO OUR BUSINESS

    The development and commercialization of non-viral adoptive TCR-T cell therapies could be considered a new approach to cancer treatment, the successful development of which is subject to significant challenges

  • DroppedRISKS RELATED TO OUR BUSINESS

    unless we revoke the notice to terminate the Patent License or subsequently acquire substantially similar rights, our inability to use the technology currently licensed to us pursuant to the Patent License

  • DroppedRISKS RELATED TO OUR BUSINESS

    Any termination of our licenses with MD Anderson or our research and development agreements with MD Anderson could result in the loss of significant rights and could significantly harm our ability to develop and commercialize our product candidates

    Challenges specific to the development of non-viral adoptive TCR-T cell therapies for cancer.

  • DroppedRISKS RELATED TO OUR BUSINESS

    the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us

    Risks related to the potential inability to use technology licensed from the Patent License.

  • DroppedRISKS RELATED TO OUR BUSINESS

    We may not be able to retain the rights licensed to us and Precigen by MD Anderson to technologies relating to TCR-T cell therapies and other related technologies

    Risks of termination of licenses or research and development agreements with MD Anderson.

  • DroppedRISKS RELATED TO OUR BUSINESS

    Should we resume development of our TCR-T product candidates, we may not be able to commercialize them, generate significant revenues, or attain profitability

    Intellectual property ownership allocation disputes with licensors like MD Anderson and Precigen.

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must approve any replacement contractor

    Risks of losing rights licensed from MD Anderson for TCR-T cell therapies.

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products

    Risks that TCR-T product candidates might not be commercialized or generate revenues if resumed.

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Our future contract manufacturers may not perform as agreed or may remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    If any third party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovations

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    regulatory determinations to temporarily or permanently cease enrollment for other reasons not related to patient safety

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenues

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    The risk that patients enrolled in clinical trials will drop out of the clinical trials before the manufacturing and infusion of our product candidates or clinical trial completion

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates, should we resume development

    Risks of being unable to identify manufacturers on acceptable terms and FDA approval requirements for replacements.

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition and prospects significantly

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    demand for our product candidates, which could adversely and materially affect our ability to conduct clinical trials, should we resume them, which could significantly harm our business

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    We may have difficulty validating our manufacturing process as we manufacture our product candidates from an increasingly diverse patient population for our clinical trials, should we resume these activities

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    The gene transfer vectors from our Sleeping Beauty system used to manufacture our TCR-T product candidates may incorrectly modify the genetic material of a patient’s T cells, potentially triggering the development of a new cancer or other adverse events

  • DroppedRISKS RELATED TO THE PRECLINICAL, CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES

    Injunctions or the imposition of civil or criminal penalties

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    Our inability to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate would cause our business to suffer significantly

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    Diminish any competitive advantages that we may otherwise enjoy

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    If physicians and patients do not accept and use our product candidates, once approved, our ability to generate revenue from sales of our products will be materially impaired

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    The price at which we sell our products

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    Our ability to generate product revenues will be diminished if our products do not obtain coverage and adequate reimbursement from payors

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    The market opportunities for our TCR-T product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    may not be amenable to treatment with our product candidates. Our market opportunities may also be limited by competitor treatments that may enter the market

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory enactments in recent years that change the healthcare system in ways that could impact our future ability to sell our product candidates profitably

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected

  • DroppedRISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES

    To the extent that any of our product candidates is ultimately sold in a foreign country, we may be subject to similar foreign laws and regulations

Reworded

  • 92% rewrittenRISKS RELATED TO OUR BUSINESS

    A decline in our share price

    The risk heading was changed to reflect a decline in share price while maintaining existing insurance adequacy language.

  • 87% rewrittenRISKS RELATED TO OUR BUSINESS

    We may become involved in litigation, including securities class action litigation, that could divert management’s attention and harm the Company’s business, and insurance coverage may not be sufficient to cover all costs and damages

  • 85% rewrittenRISKS RELATED TO OUR BUSINESS

    Further, if our common stock is delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market

    Added specific mentions of material weaknesses in internal controls and compliance requirements under the Sarbanes-Oxley Act.

  • 80% rewrittenRISKS RELATED TO STOCK OWNERSHIP IN OUR COMPANY AND OTHER RISKS

    Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock

    Updated executive and director beneficial ownership figures to approximately 25.71%, including 17.47% held by Robert W. Postma.

  • 76% rewrittenRISKS RELATED TO STOCK OWNERSHIP IN OUR COMPANY AND OTHER RISKS

    We are a “smaller reporting company,” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors

  • 53% rewrittenRISKS RELATED TO STOCK OWNERSHIP IN OUR COMPANY AND OTHER RISKS

    Our business could be materially and negatively affected as a result of the actions of activist stockholders

  • 52% rewrittenRISKS RELATED TO OUR INTELLECTUAL PROPERTY

    Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements

  • 43% rewrittenRISKS RELATED TO OUR INTELLECTUAL PROPERTY

    If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully develop our product candidates may be materially impaired

    Added the word legacy before TCR-T related patent portfolio to reflect the pivot away from cancer cell therapies.

  • 32% rewrittenRISKS RELATED TO OUR BUSINESS

    Our operating history makes it difficult to evaluate our business and prospects

  • 30% rewrittenRISKS RELATED TO STOCK OWNERSHIP IN OUR COMPANY AND OTHER RISKS

    Discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us

  • 28% rewrittenRISKS RELATED TO OUR BUSINESS

    Conducting sales and marketing activities

All 42 risk factors

Headings as the filing states them, in filing order.

RISKS RELATED TO OUR REPRIORITIZATION, FINANCIAL POSITION AND CAPITAL REQUIREMENTS

  1. 01We are not actively pursuing broad strategic alternatives such as acquisitions, mergers, or sales of the Company. Our primary focus is advancing our internally developed small-molecule Obesity and Metabolic Disorders ProgramNew
  2. 02The process of advancing our Obesity and Metabolic Disorders Program is costly and resource-intensive. We have incurred, and will continue to incur, significant costs related to preclinical studies, formulation development, manufacturing, and regulatory activitiesNew
  3. 03We have no committed sources of additional capital at this time. Accordingly, we could exhaust our current cash resources before we are able to meaningfully advance our Obesity and Metabolic Disorders Program, requiring the Company to raise additional capital on uncertain terms or at allNew
  4. 04We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable futureNew
  5. 05incur additional costs associated with current and future research, development and commercialization efforts and operations as a public companyNew
  6. 06If we are unable to successfully advance our obesity and metabolic disorders program or raise sufficient additional capital, our Board of Directors may ultimately decide to pursue a dissolution and liquidationNew

RISKS RELATED TO OUR BUSINESS

  1. 07Further, if our common stock is delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market85% rewritten
  2. 08Because we currently have only one full-time employee—our Chief Executive Officer—who performs or oversees multiple functions, and we rely on outside consultants (including for accounting and financial reporting functions)New
  3. 09We have no products approved for commercial sale and have not generated any revenue from product sales. We may never generate any revenue from product sales or become profitable and, if we achieve profitability, we may not be able to sustain itNew
  4. 10enforce and defend intellectual property rights and claimsNew
  5. 11Our business is highly dependent on the success of our Obesity and Metabolic Disorders Program, which is in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and commercially launch a productNew
  6. 12potent for each desired indication. An NDA must also include significant information regarding the chemistry, manufacturing and controls for the productNew
  7. 13Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our businessNew
  8. 14We face competition from entities that have developed or may develop programs for the medical needs we plan to address with our Obesity and Metabolic Disorders ProgramNew
  9. 15Our operating history makes it difficult to evaluate our business and prospects32% rewritten
  10. 16Conducting sales and marketing activities28% rewritten
  11. 17Our business subjects us to the risk of liability claims associated with the use of hazardous materials and chemicals
  12. 18We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits
  13. 19A decline in our share price92% rewritten
  14. 20Our legacy TCR-T cell therapy programs and related intellectual property are no longer in active development and may not generate any meaningful valueNew
  15. 21and development activities, pursuant to which we agreed to pay $285,000 in six installments through May 30, 2026. Residual obligations, including trial close-out and long-term follow-up, may result in limited ongoing payments or interactionsNew
  16. 22Our ability to advance our Obesity and Metabolic Disorders Program depends on our ability to retain our remaining employee and consultantsNew
  17. 23Any future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employeesNew
  18. 24We may become involved in litigation, including securities class action litigation, that could divert management’s attention and harm the Company’s business, and insurance coverage may not be sufficient to cover all costs and damages87% rewritten

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

  1. 25If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully develop our product candidates may be materially impaired43% rewritten
  2. 26That we will not need to initiate litigation and/or administrative proceedings that may be costly whether we win or lose
  3. 27If we are unable to protect the confidentiality of our confidential information, our business and competitive position would be significantly harmed
  4. 28Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products
  5. 29Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements52% rewritten
  6. 30We license rights to products and technology that are important to our business, and we expect to enter into additional licenses in the futureNew
  7. 31In addition, in certain cases, the rights licensed to us are rights of a third party licensed to our licensor. In such instances, if our licensors do not comply with their obligations under such licenses, our rights under our license agreements with our licensor may be adversely affected
  8. 32We may be subject to claims by third parties asserting that our employee or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property

RISKS RELATED TO STOCK OWNERSHIP IN OUR COMPANY AND OTHER RISKS

  1. 33Our stock price has been, and may continue to be, volatile
  2. 34Changes in accounting principles
  3. 35Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult
  4. 36Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit
  5. 37Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted
  6. 38If securities' and/or industry analysts' recommendations change adversely or if our business, financial condition, results of operations, cash flows or prospects do not meet their expectations, our stock price and trading volume could significantly decline
  7. 39Our business could be materially and negatively affected as a result of the actions of activist stockholders53% rewritten
  8. 40Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock80% rewritten
  9. 41Discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us30% rewritten
  10. 42We are a “smaller reporting company,” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors76% rewritten

Other Alaunos Therapeutics 10-Ks

  • FY2024 10-K risk factors
    61 risks

    Company is evaluating strategic alternatives following a 95% workforce reduction in August 2023. Future depends on finding a strategic transaction or liquidating assets. Licensed TCR-T cell therapies and clinical programs are currently suspended or uncertain.

    Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.